Are ASML capacity fears overdone? UBS weighs in By Investing.com

The market is still underpricing how much of ASML’s earnings power is now driven by mix and throughput rather than headline unit growth. If capacity expands without proportional capex inflation, the next leg of margin expansion comes from fixed-cost absorption and service intensity, which means the stock can rerate even in a relatively ordinary order environment. That makes the 2026-2027 window more important than the next quarter: the setup is for a slow-burn earnings compounding story, not a single catalyst trade.

The real second-order winner is the broader semiconductor capital equipment stack, especially deposition and etch, because leading-edge spending is being deferred rather than destroyed. If lithography spend spills into the following year, the market may be mis-sequencing the cycle and over-penalizing litho near-term while underappreciating downstream equipment beneficiaries into 2026. On the flip side, China remains the clearest source of estimate risk: not because demand disappears, but because timing mismatches can create a false negative on growth and keep sentiment depressed longer than fundamentals warrant.

The most interesting contrarian angle is that ASML may be a better quality compounder than a cyclical high beta name into 2027. If High NA adoption stays on schedule and productivity gains hold, the market could be too conservative on terminal margin and too focused on near-term China softness. The key risk is a prolonged order digestion phase that delays lithography recovery by another 2-3 quarters, which would cap multiple expansion despite healthy longer-term fundamentals.